Gene therapy shows promise for rare blindness disease
NCT ID NCT04794101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a follow-up to a Phase 3 trial testing a gene therapy called AAV5-hRKp.RPGR for people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. The treatment aims to slow or stop vision decline by delivering a working copy of the RPGR gene to the retina. Researchers are monitoring 97 participants for side effects and changes in eyesight over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli
Naples, 80131, Italy
-
Azienda Ospedaliero Universitaria Careggi
Florence, 50134, Italy
-
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Paris, 75012, France
-
Childrens Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Duke Eye Center
Durham, North Carolina, 27705, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Gartnavel General Hospital
Glasgow, G12 0YN, United Kingdom
-
Ghent University Hospital
Ghent, 9000, Belgium
-
Hadassah Medical Center
Jerusalem, 91120, Israel
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hospital For Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS
Rome, 00184, Italy
-
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, 02114, United States
-
Moorfields Eye Hospital
London, EC1V 2PD, United Kingdom
-
NHS Lothian
Edinburgh, EH3 9HA, United Kingdom
-
Ospedale San Paolo
Milan, 20142, Italy
-
Radboudumc
Nijmegen, 6525EX, Netherlands
-
Retina Consultants of Houston
Bellaire, Texas, 77401, United States
-
Rigshospitalet Glostrup
Glostrup Municipality, 2600, Denmark
-
Shiley Eye Institute Jacobs Retina Center
La Jolla, California, 92093 0946, United States
-
St James University Hospital
Leeds, LS9 7TF, United Kingdom
-
Stanford Health Care
Palo Alto, California, 94303, United States
-
Univ of Michigan Medical Center
Ann Arbor, Michigan, 48105, United States
-
Universite de Lausanne, Hopital ophtalmique Jules-Gonin
Lausanne, 1004, Switzerland
-
University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical
Basel, 4031, Switzerland
-
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania, 15213, United States
-
VUMC Amsterdam
Amsterdam, 1105AZ, Netherlands
-
VitreoRetinal Associates, PA
Gainesville, Florida, 32607, United States